#NewMemberAseBio | "AseBio is the door to the networking with key relevant stakeholders in the biomedical innovation and development"

AseBio. What does your company's work bring to the table and what is its strength?

Marina Rigau. MiMARK Diagnostics, S.L is a women’s health company that aims revolutionizing gynaecological diagnostics. We are a pipeline company developing innovative and minimal invasive diagnostic assays based on gynaecological fluids that will provide women suffering from gynecological conditions a faster, accurate and accessible diagnosis, positively impacting their lives. We envision gynaecological fluids as the next step liquid biopsy for unmet clinical gynaecological needs. Our proof of concept and most advanced product in our pipeline is WomEC, a diagnostic test for Endometrial Cancer. MiMARK is composed by a strong multidisciplinary and passionate team, which is highly committed with patients, society, and healthcare systems. We are eager to learn and adapt while ensuring quality and efficiency in each step. 

AseBio. What is AseBio for you?

Marina Rigau. AseBio means transformation by identifying, understanding, communicating, and sharing the global challenges in the biotechnology sector. AseBio’s vision aims positioning Spain to the next era in which biotechnological sector is highly valued as a leading R&D country. 

AseBio for us is the door to the networking with key relevant stakeholders in the biomedical innovation and development as well as investors and leading biotechnology companies in Spain which whom we would like to stablish present and future fruitful partnerships. Is the door to knowledge, best practices’ models, policies related to our field that will impact us.

 

AseBio. When did you first hear about AseBio?

Marina Rigau. Already when we were studying in University, we were aware of AseBio. This demonstrates the solidity and work promoted by the association, running for 20 years now, and still generating interest and increasing number of people joining.

AseBio. What do you expect from being part of an association like AseBio?

Marina Rigau. We are confident by saying AseBio will provide support, as well as the tools that MiMARK needs to grow milestone by milestone. We expect fruitful relations, networking, and cooperation with other AseBio partners to accelerate our innovation, development and commercialization of our products, but at the same time, contributing to partner’s and AseBio goals. 

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Marina Rigau. The biggest challenges are trust and action. We need society to understand, as we do, the importance and value of the biotech sector. Society needs to appreciate the sector and feel part of it. Only then we will be able to work together towards this transformation. Likewise, it will require huge efforts to activate and promote the sector in order to generate opportunities and summing committed people to the cause.